Published in AIDS on January 05, 2001
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 1.92
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2008) 1.65
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr (2013) 1.56
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2010) 1.33
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J (2009) 1.20
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol (2004) 1.08
Tautomerism in drug discovery. J Comput Aided Mol Des (2010) 1.05
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses (2012) 1.03
In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother (2002) 0.98
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS (2010) 0.98
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag (2008) 0.97
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother (2006) 0.96
Inflammation and repair in viral hepatitis C. Dig Dis Sci (2008) 0.94
Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci (2005) 0.92
Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother (2004) 0.90
Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. Drug Metab Dispos (2009) 0.90
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother (2008) 0.89
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects. Antimicrob Agents Chemother (2015) 0.87
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial. Fundam Clin Pharmacol (2009) 0.87
Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother (2014) 0.85
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother (2006) 0.84
Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. BMC Infect Dis (2006) 0.83
The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrob Agents Chemother (2015) 0.83
Does HAART efficacy translate to effectiveness? Evidence for a trial effect. PLoS One (2011) 0.82
Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. Antimicrob Agents Chemother (2005) 0.81
Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther (2011) 0.80
Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother (2009) 0.79
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy (2008) 0.77
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infect Dis (2006) 0.77
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. J Antimicrob Chemother (2010) 0.77
No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects. Antimicrob Agents Chemother (2015) 0.75
The longer the better? Four years of durable, initially boosted protease treatment. AIDS (2004) 0.75
New Drugs for the Treatment of HIV Infection. Curr Infect Dis Rep (2001) 0.75
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
A comparison of the choline-esterase activities of the blood-sera from various species. Biochem J (1933) 15.78
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Proposed diagnostic criteria for neurocysticercosis. Neurology (2001) 9.15
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Accuracy of diagnosis of psychosis on general practice computer system. BMJ (1993) 4.88
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Induction of steroidogenesis in tissue culture by cholera enterotoxin. Nat New Biol (1973) 4.72
Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet (1999) 4.55
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
Psychiatrists and their patients: views on forms of dress and address. Br J Psychiatry (1997) 4.41
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell (2000) 3.87
Aetiology and management of bronchiolitis and pneumonia in childhood. Br Med J (1965) 3.76
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
The oxygen consumption of the frog's heart: I. J Physiol (1928) 3.63
Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res (1991) 3.56
Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J Psychiatry (2000) 3.49
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Straight talking: an investigation of the attitudes and practice of psychoanalysts and psychotherapists in relation to gays and lesbians. Br J Psychiatry (2001) 3.44
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Behavior modification of children with learning disabilities using grades as tokens and allowances as back up reinforcers. Except Child (1968) 3.31
Notch receptor activation inhibits oligodendrocyte differentiation. Neuron (1998) 3.30
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA (2001) 3.28
Detecting common mental disorders in primary care in India: a comparison of five screening questionnaires. Psychol Med (2007) 3.27
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation (1998) 3.14
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
The Estimation of Fat in Blood. Biochem J (1925) 3.12
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Estimating spatio-temporal receptive fields of auditory and visual neurons from their responses to natural stimuli. Network (2001) 2.85
A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med (1990) 2.83
The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry (2006) 2.80
Sexual medicine. BMJ (1997) 2.77
Chronic fatigue in general practice: is counselling as good as cognitive behaviour therapy? A UK randomised trial. Br J Gen Pract (2001) 2.76
Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59
Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine (Baltimore) (1993) 2.59
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51
Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol A Biol Sci Med Sci (1995) 2.51
Treatment of neurocysticercosis: current status and future research needs. Neurology (2006) 2.41
Aortic morphology following endovascular repair of acute and chronic type B aortic dissection: implications for management. Eur J Vasc Endovasc Surg (2008) 2.32
Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. Am Rev Respir Dis (1993) 2.31
Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis (1975) 2.27
National survey of UK psychiatrists' attitudes to euthanasia. Lancet (1998) 2.27
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
A hospital-based influenza immunization program, 1977-78. Am J Public Health (1983) 2.23
Diagnostic strategies used in primary care. BMJ (2009) 2.23
"Operation Cataract": a means of reducing waiting lists for cataract operations. BMJ (1989) 2.22
An anonymous seroprevalence survey of HIV infection among pregnant women in British Columbia and the Yukon Territory. CMAJ (1990) 2.21
Do microbiota cause emission of stibine from cot mattresses? Lancet (1995) 2.19
The disadvantages of helicopter transfer. Br J Hosp Med (1990) 2.18
Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development (2001) 2.16
Balance and strength training in older adults: intervention gains and Tai Chi maintenance. J Am Geriatr Soc (1996) 2.16
Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother (2004) 2.11
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med (2000) 2.11
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med (1996) 2.10
The red cell distribution width in sickle cell disease--is it of clinical value? Clin Lab Haematol (1991) 2.09
Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun (1983) 2.08
The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br (2009) 2.05
Prevention of diabetes. BMJ (2006) 2.05
Neurocysticercosis in Houston, Texas. A report of 112 cases. Medicine (Baltimore) (1994) 2.05
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Contributions of community involvement to organizational-level empowerment: the federal Healthy Start experience. Health Educ Behav (2001) 2.03
Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol (1987) 2.02
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med (2010) 2.00
Video networking of cardiac catheterization laboratories. Am Heart J (1999) 1.99
Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Eur J Surg Oncol (2013) 1.99
The proteases and pathogenicity of parasitic protozoa. Annu Rev Microbiol (1993) 1.96
Managing depression: cognitive behaviour therapy training for GPs. Br J Gen Pract (1997) 1.93
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst (1975) 1.91
E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol (2001) 1.91
Binding of the origin of replication of Escherichia coli to the outer membrane. Cell (1982) 1.90
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
VP7 serotype-specific glycoprotein of OSU porcine rotavirus: coding assignment and gene sequence. J Gen Virol (1986) 1.88
Simple CPR: A randomized, controlled trial of video self-instructional cardiopulmonary resuscitation training in an African American church congregation. Ann Emerg Med (1999) 1.88
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Serum distemper virus and parvovirus antibody titers among dogs brought to a veterinary hospital for revaccination. J Am Vet Med Assoc (1998) 1.87
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Nuclear Notch1 signaling and the regulation of dendritic development. Nat Neurosci (2000) 1.87
Pathways to care for patients with a first episode of psychosis. A comparison of ethnic groups. Br J Psychiatry (1995) 1.86
Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A (1993) 1.82
Neuropeptide FF and FMRFamide potentiate acid-evoked currents from sensory neurons and proton-gated DEG/ENaC channels. Neuron (2000) 1.81
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther (2015) 1.81
Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry (2001) 1.80
Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.79
At risk drinking among general practice attenders: validation of the CAGE questionnaire. Psychol Med (1986) 1.79